243 related articles for article (PubMed ID: 29778097)
1. Hyperprolactinemia-inducing antipsychotics increase breast cancer risk by activating JAK-STAT5 in precancerous lesions.
Johnston AN; Bu W; Hein S; Garcia S; Camacho L; Xue L; Qin L; Nagi C; Hilsenbeck SG; Kapali J; Podsypanina K; Nangia J; Li Y
Breast Cancer Res; 2018 May; 20(1):42. PubMed ID: 29778097
[TBL] [Abstract][Full Text] [Related]
2. Heat shock protein-90-alpha, a prolactin-STAT5 target gene identified in breast cancer cells, is involved in apoptosis regulation.
Perotti C; Liu R; Parusel CT; Böcher N; Schultz J; Bork P; Pfitzner E; Groner B; Shemanko CS
Breast Cancer Res; 2008; 10(6):R94. PubMed ID: 19014541
[TBL] [Abstract][Full Text] [Related]
3. Mucuna pruriens (L.) DC chemo sensitize human breast cancer cells via downregulation of prolactin-mediated JAK2/STAT5A signaling.
Sinha S; Sharma S; Vora J; Shah H; Srivastava A; Shrivastava N
J Ethnopharmacol; 2018 May; 217():23-35. PubMed ID: 29427634
[TBL] [Abstract][Full Text] [Related]
4. Differential add-on effects of aripiprazole in resolving hyperprolactinemia induced by risperidone in comparison to benzamide antipsychotics.
Chen CK; Huang YS; Ree SC; Hsiao CC
Prog Neuropsychopharmacol Biol Psychiatry; 2010 Dec; 34(8):1495-9. PubMed ID: 20732372
[TBL] [Abstract][Full Text] [Related]
5. Jak2/Stat5 signaling in mammogenesis, breast cancer initiation and progression.
Wagner KU; Rui H
J Mammary Gland Biol Neoplasia; 2008 Mar; 13(1):93-103. PubMed ID: 18228120
[TBL] [Abstract][Full Text] [Related]
6. [Atypical antipsychotics and sexual dysfunction: five case-reports associated with risperidone].
Haefliger T; Bonsack C
Encephale; 2006; 32(1 Pt 1):97-105. PubMed ID: 16633296
[TBL] [Abstract][Full Text] [Related]
7. CUZD1 is a critical mediator of the JAK/STAT5 signaling pathway that controls mammary gland development during pregnancy.
Mapes J; Li Q; Kannan A; Anandan L; Laws M; Lydon JP; Bagchi IC; Bagchi MK
PLoS Genet; 2017 Mar; 13(3):e1006654. PubMed ID: 28278176
[TBL] [Abstract][Full Text] [Related]
8. [Antipsychotic-drug-induced hyperprolactinemia: physiopathology, clinical features and guidance].
Besnard I; Auclair V; Callery G; Gabriel-Bordenave C; Roberge C
Encephale; 2014 Feb; 40(1):86-94. PubMed ID: 23928066
[TBL] [Abstract][Full Text] [Related]
9. Stat5 regulates the phosphatidylinositol 3-kinase/Akt1 pathway during mammary gland development and tumorigenesis.
Schmidt JW; Wehde BL; Sakamoto K; Triplett AA; Anderson SM; Tsichlis PN; Leone G; Wagner KU
Mol Cell Biol; 2014 Apr; 34(7):1363-77. PubMed ID: 24469394
[TBL] [Abstract][Full Text] [Related]
10. Crosstalk between STAT5 activation and PI3K/AKT functions in normal and transformed mammary epithelial cells.
Rädler PD; Wehde BL; Wagner KU
Mol Cell Endocrinol; 2017 Aug; 451():31-39. PubMed ID: 28495456
[TBL] [Abstract][Full Text] [Related]
11. Time course of the changes in antipsychotic-induced hyperprolactinemia following the switch to aripiprazole.
Lu ML; Shen WW; Chen CH
Prog Neuropsychopharmacol Biol Psychiatry; 2008 Dec; 32(8):1978-81. PubMed ID: 18848860
[TBL] [Abstract][Full Text] [Related]
12. Risk of breast cancer in risperidone users: A nationwide cohort study.
Reutfors J; Wingård L; Brandt L; Wang Y; Qiu H; Kieler H; Bahmanyar S
Schizophr Res; 2017 Apr; 182():98-103. PubMed ID: 27823949
[TBL] [Abstract][Full Text] [Related]
13. Coactivation of janus tyrosine kinase (Jak)1 positively modulates prolactin-Jak2 signaling in breast cancer: recruitment of ERK and signal transducer and activator of transcription (Stat)3 and enhancement of Akt and Stat5a/b pathways.
Neilson LM; Zhu J; Xie J; Malabarba MG; Sakamoto K; Wagner KU; Kirken RA; Rui H
Mol Endocrinol; 2007 Sep; 21(9):2218-32. PubMed ID: 17550976
[TBL] [Abstract][Full Text] [Related]
14. Pimozide augments bromocriptine lethality in prolactinoma cells and in a xenograft model via the STAT5/cyclin D1 and STAT5/Bcl‑xL signaling pathways.
Xiao Z; Liang J; Deng Q; Song C; Yang X; Liu Z; Shao Z; Zhang K; Wang X; Li Z
Int J Mol Med; 2021 Jan; 47(1):113-124. PubMed ID: 33155660
[TBL] [Abstract][Full Text] [Related]
15. Adjunctive aripiprazole in the treatment of risperidone-induced hyperprolactinemia: A randomized, double-blind, placebo-controlled, dose-response study.
Chen JX; Su YA; Bian QT; Wei LH; Zhang RZ; Liu YH; Correll C; Soares JC; Yang FD; Wang SL; Zhang XY
Psychoneuroendocrinology; 2015 Aug; 58():130-40. PubMed ID: 25981348
[TBL] [Abstract][Full Text] [Related]
16. Combined treatment with ruxolitinib and MK-2206 inhibits the JAK2/STAT5 and PI3K/AKT pathways via apoptosis in MDA-MB-231 breast cancer cell line.
Guvenir Celik E; Eroglu O
Mol Biol Rep; 2023 Jan; 50(1):319-329. PubMed ID: 36331743
[TBL] [Abstract][Full Text] [Related]
17. Induction of multidrug resistance transporter ABCG2 by prolactin in human breast cancer cells.
Wu AM; Dalvi P; Lu X; Yang M; Riddick DS; Matthews J; Clevenger CV; Ross DD; Harper PA; Ito S
Mol Pharmacol; 2013 Feb; 83(2):377-88. PubMed ID: 23150485
[TBL] [Abstract][Full Text] [Related]
18. Cyclophilin A Function in Mammary Epithelium Impacts Jak2/Stat5 Signaling, Morphogenesis, Differentiation, and Tumorigenesis in the Mammary Gland.
Volker SE; Hedrick SE; Feeney YB; Clevenger CV
Cancer Res; 2018 Jul; 78(14):3877-3887. PubMed ID: 29959151
[TBL] [Abstract][Full Text] [Related]
19. Effects of aripiprazole on prolactin levels in subjects with schizophrenia during cross-titration with risperidone or olanzapine: analysis of a randomized, open-label study.
Byerly MJ; Marcus RN; Tran QV; Eudicone JM; Whitehead R; Baker RA
Schizophr Res; 2009 Feb; 107(2-3):218-22. PubMed ID: 19038534
[TBL] [Abstract][Full Text] [Related]
20. Bu-Shen-Zhu-Yun decoction induces PRLR deubiquitination and JAK2/STAT5 activation via CSN5
Feng H; Zhou H; Lu J; Zhang Q; Tang X; Shang Y
Aging (Albany NY); 2021 Aug; 13(16):20418-20437. PubMed ID: 34424219
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
